TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21823549

Group type: COMPARATOR
Intervention: OM‐ER 15 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: OM‐ER 30 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OC‐CR 30 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OC‐CR 60 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: OM‐ER
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OC‐CR
Number of subjects: 35
Study: 19854420

Group type: EXPERIMENTAL
Intervention: Trunk extension endurance
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Leg press strength
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trunk extension strength
Number of subjects: 70
Study: 17181373

Group type: EXPERIMENTAL
Intervention: Rifamycin-based antituberculosis therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin (alternative rifamycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin-based regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART regimens containing nevirapine or efavirenz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of HAART initiation after antituberculosis therapy
Number of subjects: 0
Study: 14688377

Group type: EXPERIMENTAL
Intervention: Allogeneic NK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro assay and in vivo mouse model with human NK cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perugia donor-recipient KIR ligand-ligand mismatch model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural cytotoxicity model
Number of subjects: 0
Study: 12221212

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (Gln-enriched EN)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous control enteral nutrition (control EN)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both trauma patient groups (glutamine and control)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Glutamine group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 10388372

Group type: EXPERIMENTAL
Intervention: Adhesive resin (Scotchbond Multi‐Purpose Plus)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Copal varnish (Plastodent)
Number of subjects: 20
Study: 7790500

Group type: EXPERIMENTAL
Intervention: Goretex Pantaloon cast liner
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard cast without Goretex liner
Number of subjects: 72
Study: 2112165

Group type: EXPERIMENTAL
Intervention: Topical therapy with 2% mupirocin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oral erythromycin
Number of subjects: 153
Study: 113829

Group type: EXPERIMENTAL
Intervention: beta-flupenthixol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha-flupenthixol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 6416510

Group type: EXPERIMENTAL
Intervention: Human insulin (insulin A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Porcine insulin (insulin B)
Number of subjects: 14
Study: 31216051

Group type: EXPERIMENTAL
Intervention: Concomitant use of repaglinide and clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repaglinide alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nateglinide and clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repaglinide and aspirin (without clopidogrel use)
Number of subjects: 0
Study: 28654557

Group type: EXPERIMENTAL
Intervention: GMI+tDCS
Number of subjects: 22

Group type: COMPARATOR
Intervention: GMI+sham tDCS
Number of subjects: 22
Study: 27240549

Group type: EXPERIMENTAL
Intervention: Cefuroxime administered to mothers 15-60 minutes before Caesarean section
Number of subjects: 22
Study: 23726831

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Ferguson's with Electrocautery (FEH)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study: 22963984

Group type: EXPERIMENTAL
Intervention: MDA-LDL in circulating immune complexes (IC)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: oxLDL in circulating immune complexes (IC)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: AGE-LDL in circulating immune complexes (IC)
Number of subjects: 907
Study: 20096821

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) plus metformin
Number of subjects: 50
Study: 18606054

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 16163743

Group type: EXPERIMENTAL
Intervention: Intervention by mental health professional for treatment of depression
Number of subjects: 0
Study: 12415443

Group type: EXPERIMENTAL
Intervention: Hypertonic saline/dextran solution (HSS group, n=13)
Number of subjects: 29
Study: 9915292

Group type: EXPERIMENTAL
Intervention: Amino acid-based dialysis solution
Number of subjects: 0
Study: 7587846

Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections of insulin and glipizide)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard insulin treatment (one morning injection per day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intensive therapy (stepped approach to insulin therapy)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study: 2341068

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single daily dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefazolin and Gentamicin (combined therapy every 8 hours)
Number of subjects: 40
Study: 7017488

Group type: EXPERIMENTAL
Intervention: Broncaspin (1.2 g suppositories, twice a day for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dimethylaminophenazone guaiacolglycolate (commercial form, twice a day for 14 days)
Number of subjects: 30
Study: 31094806

Group type: EXPERIMENTAL
Intervention: Meloxicam IV (5-60 mg)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 27882910

Group type: EXPERIMENTAL
Intervention: Wii-therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard physiotherapy (SPT)
Number of subjects: 32
Study: 24917588

Group type: EXPERIMENTAL
Intervention: Adhesive taping (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Daily muscle manual stretching, passive articular mobilization, and palmar splint (Group B)
Number of subjects: 70
Study: 24126211

Group type: EXPERIMENTAL
Intervention: HAC1 vaccine (90 μg non-adjuvanted)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HAC1 vaccine (15 μg and 45 μg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Approved monovalent H1N1 vaccine
Number of subjects: 80
Study: 22771827

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sorafenib (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus sorafenib 200 mg, two tablets p.o., twice daily continuously)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (gemcitabine 1000 mg/m² i.v., weekly seven times followed by 1 rest week, then weekly three times every 4 weeks plus placebo, two tablets p.o., twice daily continuously)
Number of subjects: 104
Study: 19915774

Group type: EXPERIMENTAL
Intervention: Endovascular surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 17481800

Group type: EXPERIMENTAL
Intervention: Etilefrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15361287

Group type: EXPERIMENTAL
Intervention: 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month each year from November 1989 to December 1991.
Number of subjects: 5026

Group type: COMPARATOR
Intervention: Placebo capsules containing corn oid.
Number of subjects: 5026
Study: 11550729

Group type: EXPERIMENTAL
Intervention: 5-session Preparing for the Drug Free Years Program
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: 7-session Iowa Strengthening Families Program
Number of subjects: 667

Group type: COMPARATOR
Intervention: Minimal contact control condition
Number of subjects: 667
Study: 9786103

Group type: EXPERIMENTAL
Intervention: Clomipramine 150 mg/day plus Nortriptyline 50 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clomipramine 150 mg/day plus Placebo
Number of subjects: 30
Study: 8187231

Group type: EXPERIMENTAL
Intervention: Dextran sulfate immobilized on cellulose in the Liposorber LA-15 system
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 64
Study: 3555942

Group type: EXPERIMENTAL
Intervention: Active treatment (propranolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31563497

Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score (full eight-tier model)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score (three-category model)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score (incident cases only)
Number of subjects: 1011
Study: 30817099

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 28277486

Group type: EXPERIMENTAL
Intervention: Kriens intravelar veloplasty (IVV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: non-IVV 2-flap repair
Number of subjects: 42
Study: 25015519

Group type: EXPERIMENTAL
Intervention: Drain placement in the subhepatic space (Group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No drainage (Group B)
Number of subjects: 160
Study: 23621831

Group type: EXPERIMENTAL
Intervention: En bloc stapler ligation of the renal hilum (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Separate ligation method (Group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 70
Study: 21566299

Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg daily with main meal, titrated monthly
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cinacalcet 90 mg once weekly and 120 mg midweek with main meal, titrated monthly
Number of subjects: 27
Study: 19514814

Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (LILI) at 780 nm; 7.5 mW; 292 Hz modulation for 30 seconds
Number of subjects: 123
Study: 16767577

Group type: EXPERIMENTAL
Intervention: Chromoscopy and structure enhancement
Number of subjects: 292

Group type: COMPARATOR
Intervention: Conventional colonoscopy (Control)
Number of subjects: 292
Study: 14732316

Group type: EXPERIMENTAL
Intervention: Penicillin V (q8 hourly for 10 days)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Clarithromycin (q12 hourly for 10 days)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Cefprozil (q12 hourly for 5 days)
Number of subjects: 265
Study: 11033392

Group type: EXPERIMENTAL
Intervention: Excimer laser photoastigmatic refractive keratectomy (PARK)
Number of subjects: 56
Study: 9200197

Group type: EXPERIMENTAL
Intervention: Acid etch technique (AE)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Air abrasion with no acid etch (KCP‐1000)
Number of subjects: 85
Study: 8259810

Group type: EXPERIMENTAL
Intervention: Public health nurse intervention promoting influenza immunization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Public health nurse intervention promoting safety measures
Number of subjects: 0
Study: 3935127

Group type: EXPERIMENTAL
Intervention: Sodium crompromate (SCP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 9
Study: 31249235

Group type: EXPERIMENTAL
Intervention: Screening for proteinuria using dipstick tests and protein-to-creatinine ratio
Number of subjects: 485
Study: 30024530

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 70
Study: 26114464

Group type: EXPERIMENTAL
Intervention: Living Legends program (life review writing + intergenerational exchange)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Life review writing alone
Number of subjects: 0
Study: 24081972

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1034
Study: 21246521

Group type: EXPERIMENTAL
Intervention: Adjuvant procarbazine, lomustine, and vincristine (PCV)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: INA expression
Number of subjects: 92
Study: 19200833

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16997367

Group type: EXPERIMENTAL
Intervention: Knowledge that gesture and speech were intentionally coupled (produced by the same communicator)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Knowledge that gesture and speech were not intentionally coupled (produced by different communicators)
Number of subjects: 35
Study: 15042673

Group type: EXPERIMENTAL
Intervention: Screening group (PSA testing every 2 years for 8 years)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Screening group (PSA testing)
Number of subjects: 10000
Study: 11497016

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT+)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Steroid and/or anapolan treatment (BMT-)
Number of subjects: 16
Study: 7871339

Group type: EXPERIMENTAL
Intervention: Experimental group (doctors offered a WHO textbook on drug prescription and three monthly meetings with nurses and social workers)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (doctors not offered the WHO textbook or meetings)
Number of subjects: 340
Study: 2829371

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice a day for 1 day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice a day for 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ketoconazole and vaginal econazole nitrate (control)
Number of subjects: 0
Study: 31840332

Group type: EXPERIMENTAL
Intervention: Intervention to promote symptom management and self-care
Number of subjects: 349
Study: 29551222

Group type: EXPERIMENTAL
Intervention: High-VF diet
Number of subjects: 0
Study: 28188149

Group type: EXPERIMENTAL
Intervention: Multilayered guideline presentation format
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard narrative presentation format
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Multilayered format
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard format
Number of subjects: 181
Study: 24961447

Group type: EXPERIMENTAL
Intervention: Kochujang (34.5 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24198754

Group type: EXPERIMENTAL
Intervention: 1 mg or 2 mg oromucosal nicotine spray
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo oromucosal nicotine spray
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nicotine (1 mg or 2 mg)
Number of subjects: 31
Study: 21624391

Group type: EXPERIMENTAL
Intervention: Rivastigmine 0, 3, or 6 mg daily for six consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17407823

Group type: EXPERIMENTAL
Intervention: 20 ms presentation duration for phonologically associated lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 ms presentation duration for phonologically associated lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 ms and 50 ms presentation durations for semantically associated lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zero correct recall condition for phonologically associated lists
Number of subjects: 0
Study: 16495359

Group type: EXPERIMENTAL
Intervention: Visual illusions affecting precision grasping with the left hand in left-handed subjects.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual illusions affecting precision grasping with the right hand in right-handed subjects.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural setting precision grasping in left-handed subjects using their nondominant (right) hand.
Number of subjects: 0
Study: 14966574

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy at a pressure of 0.25 MPa
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (gargle)
Number of subjects: 30
Study: 10881250

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Galantamine 32 mg/d
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d and 32 mg/d
Number of subjects: 636
Study: 9008256

Group type: EXPERIMENTAL
Intervention: 10 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 20 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Number of subjects: 550
Study: 12959315

Group type: EXPERIMENTAL
Intervention: Pazinaclone (DN‐2327) 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pazinaclone (DN‐2327) 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active metabolite MII
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pazinaclone (DN‐2327) and MII
Number of subjects: 0
Study: 3611334

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (intensive physical therapy course for 6 weeks)
Number of subjects: 12
Study: 29452134

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - 4 x 4 min bouts at 85-95% HRmax, 3 times/week
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT) - 44 min at 60-70% HRmax, 3 times/week
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nutrition advice only
Number of subjects: 99
Study: 27395413

Group type: EXPERIMENTAL
Intervention: Hypoxic confinement combined with daily moderate-intensity exercise (HAMB)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bed rest in normoxia (NBR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bed rest in hypoxia (HBR)
Number of subjects: 11
Study: 26248510

Group type: EXPERIMENTAL
Intervention: Low-dose rVSV-ZEBOV (3×10^5 pfu)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose rVSV-ZEBOV (1×10^7 pfu or 5×10^7 pfu)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24183475

Group type: EXPERIMENTAL
Intervention: 10-week fundamental motor skill programme (20 sessions of 60 minutes each, 2 per week)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 10-week fundamental motor skill programme
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no additional practice)
Number of subjects: 93
Study: 21387109

Group type: EXPERIMENTAL
Intervention: MVA-5T4 (TroVax(®))
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 18250971

Group type: EXPERIMENTAL
Intervention: CD8+ T cells expressing CD45RO
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD3+ T cells expressing activation marker CD25
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4+ T cells expressing memory marker CD45RO
Number of subjects: 0
Study: 16633098

Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12594139

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 50% FE'(N(2)O)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.025, 0.05 and 0.1 micro g kg(‐1) min(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrous oxide at 20% FE'(N(2)O)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pain (control condition)
Number of subjects: 10
Study: 10955754

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen at 2 l min(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham oxygen (carrying the portable oxygen cylinder and breathing air)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IPS at 14 cmH2O from a portable ventilator (the HIPPY)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline walk (no assistance)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham IPS (< 8 cmH2O)
Number of subjects: 10
Study: 8839325

Group type: EXPERIMENTAL
Intervention: Companion bird (experimental group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No companion bird (control group, n = 20)
Number of subjects: 40
Study: 8398588

Group type: EXPERIMENTAL
Intervention: R-verapamil 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-verapamil 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-verapamil 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 240 mg racemic verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3533370

Group type: EXPERIMENTAL
Intervention: 50 mg oral nalmefene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29577496

Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 26606735

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (DAPT) with either ticagrelor or clopidogrel for 12 months plus ASA ≤100 mg for 24 months
Number of subjects: 16000
Study: 24276953

Group type: EXPERIMENTAL
Intervention: Aprepitant (day 1: 125 mg; days 2-3: 80 mg)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Standard therapy (days 1-3: placebo)
Number of subjects: 421
Study: 22774396

Group type: EXPERIMENTAL
Intervention: Combined therapy with myo-inositol (MI) and D-chiro-inositol (DCI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Myo-inositol (MI) alone
Number of subjects: 50
Study: 20672368

Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) sessions during hospitalization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hospital stay without APA sessions
Number of subjects: 30
Study: 18301345

Group type: EXPERIMENTAL
Intervention: Transluminal balloon angioplasty (TBA) on middle cerebral artery territories (n = 57 vessel segments)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (anterior cerebral artery territories not subjected to TBA, n = 61 vessel segments)
Number of subjects: 38